Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
4,406 results in Europe PMC
PubMed plus preprints and full-text open access papers. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- SGLT2 inhibitors in diabetic biopsy proven MASH patients: A systematic review and meta-analysis.
Abdel Monem MS, Kamel AM, Abbassi MM, Sabry NA. · J Diabetes Complications · 2026 · cited 0 timesmeta-analysis, systematic review
- GLP-1 receptor agonists in metabolic dysfunction-associated steatohepatitis: a systematic review and meta-analysis of randomized controlled trials.
Sun SP, Wang CX, Yuan MK, Min H. · Hepatol Int · 2026 · cited 0 timesmeta-analysis, systematic review
- Efficacy and safety of GLP-1 receptor agonists in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH): A systematic review and meta-analysis.
Alfawaz M, Bajamaan D, Alghamdi L, Alorfi Y, Khared S, Ameen N, Alamri R, Abuladel M, Alshehri R, Altowairqi S. · Medicine (Baltimore) · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Incidence of Cirrhosis in Fibrotic Metabolic Dysfunction-Associated Steatohepatitis: A Meta-Analysis of Placebo Arms from Randomized Clinical Trials.
Khalil SM, Al-Sharif L, Diaz I, Souza M. · Dig Dis Sci · 2026 · cited 2 timesmeta-analysis, systematic review
- Effects of selective estrogen receptor modulators on lipid metabolism in patients with breast cancer: A systematic review and meta-analysis.
Wang Q, Jiang Y, Li Y, Zhao C, Lao J, Yang Y, Li X, Ding G, Yi P, Tang F. · J Cancer Res Ther · 2026 · cited 0 timesmeta-analysis, systematic review
- Updating the MASH pharmacotherapy landscape: a network meta-analysis incorporating SGLT2 inhibitors and emerging combination therapies.
Tang M, Ma Y, Wang Y. · Front Endocrinol (Lausanne) · 2026 · cited 1 timesOpen accesssystematic review, systematic-review
- Prevalence of fatty liver and diabetes mellitus in patients with fatty pancreas disorder (FPD): A meta-analysis and systematic review.
Du Y, Wang X, Li X, Liu Q, Xia Y, Yang J, Wang X, Qi L, Pandol SJ, Li L. · Diabetes Res Clin Pract · 2026 · cited 0 timesmeta-analysis, systematic review
- Beyond the Liver: Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) Associated 35% Higher Risk of Clinically Diagnosed Heart Failure With Preserved Ejection Fraction (HFpEF).
Hegazy MA, Soliman S, Ahmed MM, Attia A, Bellakhal S, Tawfik NM, Soliman AR. · Curr Cardiol Rep · 2026 · cited 0 timesmeta-analysis, systematic review
- ALG-055009 in non-cirrhotic adults with metabolic dysfunction-associated steatohepatitis (HERALD): a randomised, double-blind, placebo-controlled, phase 2a trial.
Loomba R, Wang S, Desai D, Santillano D, Lucas KJ, Neff G, Bianco AC, Bruinstroop E, Su Y, Achneck HE, Le K, Fitzgerald M, Wu M, Lin TI, Chanda SM, Blatt LM, Mantzoros CS. · Lancet Gastroenterol Hepatol · 2026 · cited 0 timesclinical trial, phase ii, multicenter study
- Therapeutic role of semaglutide in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis of placebo-controlled trials with GRADE evidence assessment.
Khan S, Jamal A, Qadri M, Zai IA, Shah A, Ahmed A, Khalid AA, Khan A, Misbahuddin FNU, Iftikhar H, Sawaira FNU, Mohmand MS, Khalil I, Khan M, Ahmed S. · Medicine (Baltimore) · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Silymarin-Based Therapies in Chronic Liver Disease: A Systematic Review of Biochemical, Cardiometabolic, Steatosis, and Fibrosis-Related Outcomes.
Lee HY, Oh H, Yoon EL, Jun DW. · Nutrients · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- EQ-5D health utility gains with once-weekly semaglutide 2.4 mg in people with MASH and F2/F3 fibrosis: An analysis of ESSENCE.
Augusto M, Bauer R, Clancy S, Poulsen AS, Tefos F, Long M. · JHEP Rep · 2026 · cited 1 timesOpen accessclinical trial, phase iii, brief-report
- Prognostic value of liver histology in steatotic liver disease: a systematic literature review and meta-analysis.
Barritt AS, Qasim A, Kim Y, Miller SD, O'Donnell J, Johnston K. · J Comp Eff Res · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Prevalence of metabolic dysfunction associated steatotic liver disease in type 2 diabetes mellitus in India: A systematic review and meta-analysis.
Singhai A, Meena R, Joshi R, Khadanga S, Jhaj R, Goyal A, Wakode S. · Indian J Med Res · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Clinical evidence of semaglutide for metabolic dysfunction-associated steatotic liver disease (MASLD): An updated meta-analysis.
Peng TR, Lin HH, Tseng TL, Wu TW, Chao YC. · Br J Clin Pharmacol · 2026 · cited 2 timesmeta-analysis, systematic review
- Dysregulated growth hormone-insulin-like growth factor-1 axis in adults with metabolic dysfunction-associated steatotic liver disease: a meta-analysis.
Messetti D, Mantovani A, Morandin R, Rolli N, Molinaroli E, Giachetti G, Zoco M, Polyzos SA, Targher G. · Nutr Metab Cardiovasc Dis · 2026 · cited 3 timesmeta-analysis, systematic review
- Simvastatin Treatment in Patients with Liver Cirrhosis: A Phase II Randomized Placebo-Controlled Trial Shows Reduction in IL6 Levels.
Hussain SK, Ayoub WS, Cruz-Correa M, Kulik LM, Smith C, Rodriguez LM, Richmond E, Umar A, Davey S, Benante K, Schering T, Kocherginsky M, Chen R, Mi X, Khan SA, Goodman MT. · Cancer Prev Res (Phila) · 2026 · cited 0 timesclinical trial, phase ii, multicenter study
- Clinical Trial: Phase 3 Trial of Resmetirom Versus Placebo in Metabolic Dysfunction-Associated Steatohepatitis-Reanalysis of Fibrosis Stage 2-3 Subset.
Mironova M, Padmanabhan K, Schneider D, Schattenberg JM, Loomba R. · Aliment Pharmacol Ther · 2026 · cited 2 timesclinical trial, phase iii, multicenter study
- The risk of Metabolic Dysfunction-Associated Steatotic Liver Disease in patients with psoriasis: An updated systematic review and meta-analysis.
Nie H, Yang L, Zhong H, Zhang Y, Wang M. · Rev Invest Clin · 2026 · cited 0 timesmeta-analysis, systematic review
- Association between the PNPLA3 I148M (rs738409) polymorphism and risk of metabolic dysfunction-associated steatotic liver disease: a meta-analysis (2015-2025).
Hamood M, Al-Salehi MA, Hussein AF, Naji KM, Rawal R. · BMC Gastroenterol · 2026 · cited 1 timesOpen accessmeta-analysis, systematic review
- Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial.
Loomba R, George J, Castera L, Francque S, Lawitz E, Shoeb A, Clausen JO, Andersen B, Larsen AB, Gluud LL. · Lancet Gastroenterol Hepatol · 2026 · cited 5 timesclinical trial, phase ii, research support, non-u.s. gov't
- Role of Gut Microbiota-derived Metabolites in the Pathogenesis and Progression of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Systematic Review.
Bhaduri G, Poddar P, Karak S, Jain R, Saboo B. · J Gastrointestin Liver Dis · 2026 · cited 0 timessystematic review
- Glucagon-like peptide-1 receptor agonists and advanced liver outcomes in type 2 diabetes: a systematic review and exploratory meta-analysis.
Hu JH, Chang ML, Huang TJ, Liu NJ, Hsieh YY. · Front Endocrinol (Lausanne) · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Prevalence and Characteristics of Hyperferritinemia in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-Analysis.
Souza M, Lima LCV, Villela-Nogueira CA. · Liver Int · 2026 · cited 1 timesmeta-analysis, systematic review
- Liver Cancer Risk and Incidence Attributable to Human Immunodeficiency Virus: A Meta-Analysis and Population-Attributable Modeling Study of Over 1.2 Million Individuals.
Zhao J, Li K, Zhang Y, Chen Y, Xu L, Hu M, Wang Y, Liu Y, Li X, Wan Z, Lu J. · Int J Cancer · 2026 · cited 1 timesmeta-analysis, systematic review
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.